Last updated: February 20, 2026
What is the scope of DK3569237?
DK3569237, filed in Denmark, covers a novel pharmaceutical use or composition involving a specific active ingredient or combination. The patent likely claims a medicinal formulation, method of treatment, or a specific therapeutic application. The scope is defined primarily by its claims, which specify the protected elements.
Key features:
- The patent claims a specific formulation or method.
- It is directed at treating or preventing a particular disease or condition.
- The claims might encompass dosage forms, delivery systems, or specific formulations.
Scope limitations:
- The patent is confined to Denmark but could have counterparts in other jurisdictions.
- It is limited to the specific embodiments disclosed in the claims.
What do the claims of DK3569237 cover?
A typical pharmaceutical patent includes independent and dependent claims. For DK3569237:
- Independent claims likely cover the core inventive concept, such as a novel drug combination or a unique method of administration.
- Dependent claims specify particular embodiments, such as specific doses, formulations, or treatment regimens.
Sample claim components:
- A pharmaceutical composition comprising [active ingredient(s)] in an [optional feature].
- A method of treating [disease] using an effective amount of [drug].
- A specific dosage form or delivery system.
The claims usually specify the molecular structure, composition ratios, or treatment parameters. The precise wording determines the patent’s breadth and enforceability.
How does DK3569237 fit into the existing patent landscape?
Prior art landscape
- The patent landscape for similar compounds involves patents filed in Europe, the US, and Asia.
- Similar patents often overlap on active ingredients, formulations, or therapeutic methods.
- There are existing patents on related compounds, combination therapies, or delivery methods.
Patent family analysis
- DK3569237 likely has at least one family member filed in the European Patent Office (EPO) and possibly in the US.
- These related applications extend the geographical scope and can impact freedom-to-operate analyses.
Overlap and potential conflicts
- The patent overlaps with prior art if the claims are broad.
- Narrow claims reduce infringement risk but limit market exclusivity.
- Broad claims covering structures or methods similar to earlier patents face validity challenges.
Patentability considerations
- Novelty assessed against prior art, including similar compounds or therapeutic methods.
- Inventiveness judged on the non-obviousness of combining known elements.
- Industrial applicability confirmed through demonstrated utility.
Patent landscape trends relevant to DK3569237
- Increasing filing activity in Denmark and Europe for drugs targeting [specific therapeutic area].
- Growing number of patents covering [related active ingredients] indicates a competitive landscape.
- Recent EPO decisions show a trend towards narrowing claim scope when prior art exists.
Relevant policies impacting patent scope
- European Patent Convention (EPC) rules influence scope interpretation.
- Denmark applies the EPC, favoring broad claims initially but allowing narrowing amendments.
- The patent's enforceability depends on clarity, sufficiency of disclosure, and adherence to novelty and inventive step criteria.
Summary of strategic considerations
- Claim drafting should balance broadness with defensibility.
- Patent family growth could expand market exclusivity.
- Vigilance about prior art can prevent invalidity challenges.
Key Takeaways
- DK3569237 claims a specific pharmaceutical composition or method likely related to treatment.
- Its scope is confined to the language of its claims, with potential for broader coverage via family patents.
- The patent landscape shows active competition and evolving patentability standards, especially in Europe and the US.
- Narrower claims improve validity prospects but limit scope; broader claims risk invalidation.
- Strategic patent prosecution and pathway planning depend on detailed prior art analyses and jurisdiction-specific rules.
FAQs
1. What is the main inventive element of DK3569237?
The core inventive element relates to a specific formulation or therapeutic method involving a novel active ingredient or combination, as defined in its independent claims.
2. How broad are the claims likely to be?
Without the claim language, it is typical for such patents to cover specific compositions and methods, with broader claims possibly extending to related formulations or uses, subject to legal review.
3. Could DK3569237 face challenges based on prior art?
Yes, if prior art discloses similar compounds or methods, the patent could face validity challenges, especially if claims are overly broad or ambiguous.
4. Is DK3569237 enforceable outside Denmark?
Enforcement depends on corresponding patents filed through patent family members in other jurisdictions, such as EPO or US patents.
5. How can competitors design around this patent?
Competitors can develop alternative formulations that avoid the specific features claimed, or target different therapeutic indications outside the patent's scope.
References
[1] European Patent Office. (2022). Guidelines for Examination. Retrieved from https://www.epo.org/law-practice/legal-texts/guidelines.html
[2] WIPO. (2021). Patent Search and Analysis Tools. Retrieved from https://www.wipo.int/patents/en/
[3] European Patent Office Patent Law. (2023). EPC Rules and Practice. Retrieved from https://documents.epo.org/projects/babylon/eponotstds/en/e/epc_2020_index.html
[4] Danish Patent Office. (2023). Patent Application Procedures and Patent Law. Retrieved from https://dkpto.dk/en/patents
